Lumos Pharma Inc expected to post a loss of 89  cents a share - Earnings Preview

Lumos Pharma

06/05/2022 22:38

* Lumos Pharma Inc  LUMO.OQ   LUMO.O  is expected to show no
change in quarterly revenue when it reports  results on May 10. 
    * ​Refinitiv's mean analyst estimate for Lumos Pharma Inc is
for a
loss of 89 cents per share. For the same quarter last year, the
company reported a loss of $1.04 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lumos
Pharma Inc
is $25.5​, above​ its last closing price of $8.18. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021              -0.92      -0.67     Beat    27
 Sep. 30 2021  -1.07       -1.07      -0.90     Beat    16
 Jun. 30 2021  -1.05       -1.03      -1.04     Missed  -0.6​
 Mar. 31 2021  -0.88       -0.87      -1.04     Missed  -19
 ​​Dec.        -0.86       -0.86      -0.31     Beat    64
 31 2020                                                
 Sep. 30 2020  -0.66       -0.64      0.21      Beat    132.6​
 Jun. 30 2020  -0.72       -0.71      -0.65     Beat    8.9
 Mar. 31 2020  -0.83       -0.82      -0.14     Beat    83
 This summary was machine generated May 6 at 21:38 GMT.  All
figures in US dollars  unless otherwise stated